Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

IASO206 em Doentes com Mieloma Múltiplo Recorrente/Refratário

6 de novembro de 2026 atualizado por: Institute of Hematology & Blood Diseases Hospital, China

Um Estudo Exploratório de Segurança e Eficácia do IASO206 em Doentes com Mieloma Múltiplo Recidivante/Refratário

This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection(In Vivo CAR-T) in Patients with Relapsed/Refractory Multiple Myeloma

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

18

Estágio

  • Fase inicial 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Tianjin, China
        • Recrutamento
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
        • Contato:
        • Investigador principal:
          • gang An

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • 18 to 75 years old, male or female;

  • Diagnosed with relapsed/refractory multiple myeloma (RRMM) according to IMWG criteria, and have received at least 2 lines of treatment including one proteasome inhibitor and one immunomodulator; with documented disease progression (based on examination data) during or within 12 months after the latest anti-myeloma treatment (subjects whose last-line treatment was CAR-T therapy are not required to have progression within 12 months);

  • Presence of measurable lesions during screening according to any of the following criteria:

    • Serum monoclonal protein (M-protein) level: ≥5 g/L f;
    • Urine M protein level ≥200 mg/24 hours;
    • Light chain multiple myeloma without measurable lesions in serum or urine: the affected serum free light chain ≥100 mg/L with abnormal serum κ/λ free light chain ratio;
  • BCMA expression on MM cells determined by flow cytometry or pathology immunohistochemistry;

  • ECOG score ≤ 2;

  • Expected survival time ≥12 weeks;

  • Subjects must have adequate organ function:

  • Hematology: Absolute neutrophil count (ANC) ≥ 1×10^9/L (supportive treatment within 7 days before laboratory test is not allowed); Absolute lymphocyte count (ALC) )≥0.3×10^9/L; platelets≥50×10^9/L (blood transfusion support within 7 days before laboratory test is not allowed); hemoglobin ≥60 g/L (without red blood cell [RBC] transfusion within 7 days before laboratory test);

    • Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤1.5×upper limit of normal (ULN); serum total bilirubin≤1.5×ULN;
    • Renal function: creatinine clearance calculated according to Cockcroft-Gault formula≥ 40 ml/min.
    • Coagulation function: fibrinogen ≥1.0 g/L; activated partial thromboplastin time≤1.5×ULN, prothrombin time (PT)≤1.5×ULN;
    • Blood oxygen saturation>91%;
    • Left ventricular ejection fraction (LVEF) ≥50%;
  • Subjects and their spouses agree to use effective contraceptive methods with tools or drugs from the time the subject signs the informed consent form until one year after administration;

  • Subjects must sign a written informed consent form approved by the ethics committee before initiating the screening process.

Exclusion Criteria:

  • Patients with suspected or confirmed central nervous system involvement by plasma cell neoplasms;

  • Multiple myeloma patients with plasma cell leukemia;

  • Patients with amyloidosis;

  • Patients who have received autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks before enrollment, or have a history of allogeneic hematopoietic stem cell transplantation (Allo-HSCT);

  • Patients who have received previous BCMA-targeted therapy;

  • Patients who have received plasma cell-targeted cellular therapy within 3 months before the screening period, or in whom received cellular therapy products can still be detected in peripheral blood;

  • Patients who have received other anti-tumor treatments requires an appropriate washout period:

    • Received Bendamustine, fludalabine or high-dose cyclophosphoyl within 9 months before enrollment,or;
    • Received Monoclonal antibody treatment for multiple myeloma within 21 days before enrollment, or;
    • Received cytotoxic chemotherapy or proteasome inhibitor treatment within 14 days before enrollment, or;
    • Received immunomodulatory treatment within 7 days before enrollment, or;
    • Received other anti-tumor treatments (including but not limited to experimental drugs) listed above within 14 days before enrollment or at least 5 half-lives (whichever is longer);
  • Patients requiring long-term use of therapeutic doses of corticosteroids during the study period (defined as prednisone or equivalent >20 mg/day), except for physiological replacement, topical, and inhaled use;

  • Severe heart diseases:including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ grade III), severe arrhythmia,hypertension that cannot be controlled by medication;

  • Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases;

  • Patient who needs chronic use of immunosuppressive agents;

  • Patients with malignant tumors other than multiple myeloma within 5 years before screening, excluding fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and those after radical resection Ductal carcinoma in situ of breast and papillary thyroid carcinoma;

  • Patients with a history of solid organ transplantation;

  • Major surgery history within 2 weeks before entering the study, or scheduled surgery during the study period or within 2 weeks after the study treatment;

  • Serious uncontrolled infections during screening: Bacterial, viral, fungal, etc. infections;

  • Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and detectable hepatitis B virus (HBV) DNA in peripheral blood; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus ( HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA test positive; syphilis test positive;

  • Patients who have received inactivated vaccines within 4 weeks before enrollment;

  • Women who are pregnant or breastfeeding;

  • Patients with mental illness, consciousness disorder, or central nervous system diseases, including but not limited to epilepsy or a history of Parkinson's disease;

  • Known severe allergic reaction to IASO206 or its formulation components (such as tocilizumab);

  • Patients with unresolved non-hematological toxic reactions from previous treatments, which have not returned to baseline or ≤Grade 1 (except for alopecia and Grade 2 peripheral neuropathy);

  • Other situations considered unsuitable by the investigator.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: IASO206

IASO206 will be administered in one infusion.

The third-generation self-inactivating lentiviral vector that carries a BCMA-targeted CAR.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
The incidence and severity of adverse events(AEs)
Prazo: up to 2 years after IASO206 infusion

Cytokine release syndrome (CRS) and ICANS would be graded according to the ASTCT consensus.

All other AEs would be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

up to 2 years after IASO206 infusion

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Overall response rate (ORR)
Prazo: up to 2 years after IASO206 infusion

The proportions of subjects achieving stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR) after IASO206 infusion.

up to 2 years after IASO206 infusion
Time to response (TTR)
Prazo: up to 2 years after IASO206 infusion

The time from the start of the drug infusion in subjects to the first occurrence of sCR, CR, VGPR, or PR.

up to 2 years after IASO206 infusion
MRD negativity rate
Prazo: up to 2 years after IASO206 infusion

The proportion of subjects who achieve MRD-negativity after IASO206 infusion.

up to 2 years after IASO206 infusion
Duration of response (DOR)
Prazo: up to 2 years after IASO206 infusion

The time from the first assessment of sCR or CR or VGPR or PR to the first assessment of disease progression or death from any cause.

up to 2 years after IASO206 infusion
Progression-free survival (PFS)
Prazo: up to 2 years after IASO206 infusion

The time from the date IASO206 infusion to the date of first disease progression or death from any cause (whichever occurs first)

up to 2 years after IASO206 infusion
Overall survival (OS)
Prazo: up to 2 years after IASO206 infusion

The time from the date of IASO206 infusion to the date of death from any reason.

up to 2 years after IASO206 infusion
Pharmacodynamics(PD)
Prazo: up to 2 years after IASO206 infusion

The levels of cytokines (IL-6, serum ferritin, CRP) in peripheral blood at each time point,and lymphocyte subsets after IASO206 infusion.

up to 2 years after IASO206 infusion
Pharmacokinetic Analysis(PK)
Prazo: up to 24 month after IASO206 infusion

Maximum concentration (Cmax) of IASO206 particle and CAR-T cells.

up to 24 month after IASO206 infusion
Pharmacokinetic Analysis(PK)
Prazo: up to 24 month after IASO206 infusion

Time of maximum concentration (Tmax) of IASO206 particle and CAR-T cells.

up to 24 month after IASO206 infusion
Pharmacokinetic Analysis(PK)
Prazo: up to 24 month after IASO206 infusion

Area under the concentration versus time curve: IASO206 particle AUC0-12d; CAR-T cell AUC0-28d,AUC0-90d,AUC0-180d,AUC0-last

up to 24 month after IASO206 infusion

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

8 de janeiro de 2026

Conclusão Primária (Estimado)

15 de dezembro de 2026

Conclusão do estudo (Estimado)

15 de outubro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

9 de dezembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de dezembro de 2025

Primeira postagem (Real)

7 de janeiro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

9 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

6 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • IIT2025097

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .